By Mill Chart
Last update: Jul 2, 2025
EXELIXIS INC (NASDAQ:EXEL) was identified by our Decent Value stock screener as a company with solid fundamentals and an attractive valuation. The biotech firm specializes in developing treatments for difficult-to-treat cancers and currently has four marketed products, including its flagship drug cabozantinib.
EXEL scores an 8/10 on valuation, indicating it may be priced below its intrinsic value:
With a 9/10 health rating, EXEL maintains a strong balance sheet:
The company earns an 8/10 profitability score:
EXEL’s 8/10 growth rating reflects strong expansion:
Our Decent Value screener lists more stocks with similar characteristics.
For a deeper dive, review the full fundamental analysis of EXEL.
This is not investment advice. Always conduct your own research before making financial decisions.
43.62
-0.46 (-1.03%)
Find more stocks in the Stock Screener
EXELIXIS (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, zero debt, and robust growth prospects, making it a candidate for value investors.
EXELIXIS (NASDAQ:EXEL) is a strong growth stock with breakout potential, backed by robust earnings, revenue growth, and a healthy technical setup.
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors. The stock is consolidating with clear support levels, suggesting a potential breakout opportunity.
EXELIXIS INC (NASDAQ:EXEL) shows strong growth momentum and meets Minervini’s trend criteria, making it a stock to watch for high-growth investors.
Wondering what's happening in Monday's pre-market session? Find an overview in this article.
EXELIXIS INC (NASDAQ:EXEL) meets key growth investing criteria with strong earnings, revenue growth, and profitability, making it a standout for investors following Louis Navellier's strategy.
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.